Adverse events40

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 40

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk	Events
other	Injection site irritation	General disorders	ZYPREXA	0	98	0
other	Injection site irritation	General disorders	Cohort 1: Olanzapine (Fast-D)	2	29	2
other	Injection site irritation	General disorders	Cohort 2: Olanzapine (To-be-marketed)	0	31	0
other	Injection site irritation	General disorders	Cohort 3: Olanzapine (Slow-C)	1	31	1
other	Injection site pain	General disorders	ZYPREXA	0	98	0
other	Injection site pain	General disorders	Cohort 1: Olanzapine (Fast-D)	2	29	2
other	Injection site pain	General disorders	Cohort 2: Olanzapine (To-be-marketed)	3	31	3
other	Injection site pain	General disorders	Cohort 3: Olanzapine (Slow-C)	0	31	0
other	Urinary tract infection	Infections and infestations	ZYPREXA	5	98	5
other	Urinary tract infection	Infections and infestations	Cohort 1: Olanzapine (Fast-D)	0	29	0
other	Urinary tract infection	Infections and infestations	Cohort 2: Olanzapine (To-be-marketed)	2	31	2
other	Urinary tract infection	Infections and infestations	Cohort 3: Olanzapine (Slow-C)	0	31	0
other	Alanine aminotransferase increased	Investigations	ZYPREXA	1	98	1
other	Alanine aminotransferase increased	Investigations	Cohort 1: Olanzapine (Fast-D)	0	29	0
other	Alanine aminotransferase increased	Investigations	Cohort 2: Olanzapine (To-be-marketed)	1	31	1
other	Alanine aminotransferase increased	Investigations	Cohort 3: Olanzapine (Slow-C)	2	31	2
other	Aspartate aminotransferase increased	Investigations	ZYPREXA	1	98	1
other	Aspartate aminotransferase increased	Investigations	Cohort 1: Olanzapine (Fast-D)	0	29	0
other	Aspartate aminotransferase increased	Investigations	Cohort 2: Olanzapine (To-be-marketed)	1	31	1
other	Aspartate aminotransferase increased	Investigations	Cohort 3: Olanzapine (Slow-C)	2	31	2

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06319170/events

API reference For AI assistants

Adverse events40

Sources 3

Read this list from software.